About Christoph Schäfer

This author has not yet filled in any details.
So far Christoph Schäfer has created 54 blog entries.

Approval received for innovative vial adaptor, available now for market introduction

Bubendorf, Switzerland, Friday, August 30, 2018 – CIS Pharma announces the approval of a vial adaptor specific for the preparation and injection of intracameral cefuroxime. Consequently, the adaptor was produced [...]

Antibody-drug conjugate market with an estimated CAGR of 19%

New York, USA, Thursday, August 23, 2018 - The advancement in the medical technology is driving the global market for antibody-drug conjugates. Preclinical research, the increasing research activities on antibody [...]

CIS Pharma initiates a new R&D program on antibody-radionuclide conjugates

Bubendorf, Switzerland, Tuesday, July 10, 2018 - Over the course of the past months, CIS Pharma has developed concepts and strategies to conjugate  radioisotopes onto its polymer-drug carriers. First syntheses [...]

Intracameral cefuroxime launched in Europe

Bubendorf, Switzerland, Monday, February 26, 2018  - CIS Pharma’s licensee has launched intracameral cefuroxime across Europe. Among others, cataract clinics in France, Germany, Spain, Italy and Netherlands will be supplied [...]

CIS Pharma team attends Pharmapack 2018 in Paris

Paris, France, Wednesday to Thursday, February 7 to 8, 2018 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the two-day conference in Paris. The [...]

CIS Pharma has reached the first milestone in its SNI funded project

Bubendorf, Switzerland, Thursday, December 21, 2017 - CIS Pharma’s bio-membrane project has reached the first milestone. The polymer chemistry experts developed the a first prototype compatible with the 3D printing [...]

CIS Pharma Christmas event at Palazzo Colombino

Basel, Switzerland, Friday, December 8, 2017 - We spend the night at Palazzo Colombino, a Variété that offers a night with delishes food and spectacular artistic performances. The exquisite dishes [...]

CIS Pharma team attends CPhI Worlwide 2017 in Frankfurt

Frankfurt, Germany, Tuesday to Thursday, October 24 to 26, 2017 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Frankfurt. The [...]

CIS Pharma verified compatibility of its polymer-drug carriers to be used in antibody-drug conjugates and antibody-radionuclid conjugates

Bubendorf, Switzerland, Monday, October 16, 2017 - The polymer experts from CIS Pharma successfully accomplished a first proof-of-concept study on the compatibility of their polymer-drug carriers with a conjugation technique [...]

Mylotarg, a new antibody-drug conjugate, ADC, approved by the FDA for treatment of acute myeloid leukemia

Maryland, USA, Friday, September 1, 2017 - The U.S. Food and Drug Administration approved the ADC Mylotarg, gemtuzumab ozogamicin, for the treatment of adults with newly diagnosed acute myeloid leukemia, [...]